The ASPRE trial demonstrated that first-trimester combined screening (maternal factors + uterine artery Doppler + PlGF + PAPP-A) with low-dose aspirin (150 mg/night) from 11–14 weeks reduced the risk of:
- A Term pre-eclampsia by approximately 62%
- B Pre-term pre-eclampsia by approximately 62% ✓
- C Eclampsia in all trimesters by 50%
- D Gestational hypertension by 40%
Correct answer: B. Pre-term pre-eclampsia by approximately 62%
Explanation
The ASPRE trial showed that in women identified as high-risk by first-trimester combined screening, low-dose aspirin 150 mg nightly from 11–14 weeks to 36 weeks reduced pre-term (< 37 weeks) pre-eclampsia by approximately 62% compared with placebo. The effect on term pre-eclampsia was not significant, highlighting that the intervention is most effective for the early-onset, placentation-related subtype.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.